Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F annual reports and Form 6‑K current reports. This SEC filings page on Stock Titan centralizes those documents and pairs them with AI‑generated summaries to help readers understand the regulatory information associated with Immuron’s biopharmaceutical business.
Recent Form 6‑K filings furnished by Immuron reference Australian Securities Exchange announcements such as applications for quotation of securities, cleansing notices, CEO addresses, annual general meeting results, changes of director interests, changes of share registry, and clinical and regulatory milestones including FDA approval of the IMM‑529 Investigational New Drug application. These filings provide context on capital management, governance decisions and progress in the company’s clinical programs for Travelan/IMM‑124E, IMM‑529 and IMM‑986.
On this page, you can review Immuron’s 20‑F annual report for a comprehensive description of its operations, risk factors and financial statements, and browse 6‑K current reports that capture material information first released to the Australian Securities Exchange. Where applicable, Stock Titan also surfaces Form 4 and related insider transaction disclosures that are filed in connection with changes in director or executive holdings, as referenced in Immuron’s 6‑K exhibits.
Stock Titan’s AI features highlight key points from lengthy filings, explain technical sections in plain language, and help you locate items such as clinical trial updates, securities issuances and shareholder meeting outcomes. This makes it easier to track how Immuron’s regulatory disclosures align with its strategy in orally delivered targeted polyclonal antibodies and its commercial and clinical activities.
Immuron Limited filed a Form 6-K to share an Australian Securities Exchange announcement that its CEO, Steven Lydeamore, will present virtually at the Emerging Growth Conference on 7 May 2026 from 10:15am to 10:45am U.S. Eastern Time. The notice includes registration and question-submission details for the event.
The accompanying presentation materials describe Immuron’s focus on orally delivered, targeted polyclonal antibodies for infectious diseases and highlight key products, including Travelan® for travelers’ diarrhea, investigational candidate IMM-529 for recurrent C. difficile infection, and ProIBS® for irritable bowel syndrome symptoms.
Immuron Ltd Chief Scientific Officer Jerry Kanellos filed an initial ownership report showing his existing equity position. He directly holds 333,000 Ordinary Shares of Immuron.
He also holds Performance Rights over 272,134 underlying Ordinary Shares with a 0.0000 exercise price expiring on June 30, 2029, and additional Performance Rights over 179,664 underlying Ordinary Shares with a 0.0000 exercise price expiring on July 12, 2027. A footnote states these Performance Rights became exercisable as to 217,707 shares on July 23, 2025 and 54,427 shares on October 29, 2025.
Immuron Ltd filed an initial statement of beneficial ownership on Form 3 for Aaron James Laurita, who serves as Chief Financial Officer. The filing does not report any share transactions or holdings in either common stock or derivative securities, indicating this is a baseline regulatory disclosure as he becomes a reporting insider.
Immuron Ltd director Jeannette Anne Joughin has disclosed option holdings over the company’s Ordinary Shares. She holds options over 1,000,000 Ordinary Shares with an exercise price of $0.0789 per share, expiring on October 3, 2029. These options became exercisable as to 333,333 shares on December 9, 2024, and will become exercisable as to 333,333 shares on December 9, 2026 and 333,334 shares on December 9, 2027.
She also holds options over 333,333 Ordinary Shares with an exercise price of $0.0932 per share, expiring on June 19, 2028. Both option grants are reported as directly owned and reflect existing derivative positions rather than new market purchases or sales.
Immuron Ltd’s Chief Executive Officer Steven George Lydeamore has filed an initial ownership report. He directly holds 3,155,047 Ordinary Shares. He also holds 1,778,734 Performance Rights that vest upon achievement of performance milestones and options over 1,430,000 Ordinary Shares with a USD exercise price of $0.0861 per share, expiring on June 27, 2026.
Immuron Ltd director Ravi Savarirayan has filed an initial Form 3 detailing his ownership in the company. He reports direct ownership of 409,090 Ordinary Shares and indirect ownership of 468,750 Ordinary Shares through joint ownership with Sophie Beaumont.
He also holds options over 1,000,000 Ordinary Shares at an exercise price of $0.0789 per share, expiring on October 3, 2029, and options over 333,333 Ordinary Shares at an exercise price of $0.1040 per share, expiring on August 20, 2028. Footnotes describe staged vesting of these options across 2025–2028 and indicate the exercise prices were originally denominated in Australian dollars and translated into U.S. dollars using a Reserve Bank of Australia exchange rate.
Immuron Limited reports continued unaudited sales growth for its over-the-counter gastrointestinal supplement Travelan® in Q3 FY26. In Australia, Travelan® sales rose 15% on the prior corresponding period, helped by digital and social media marketing, stronger in-store promotion, new banner-group store listings, and increased South East Asian travel.
In the U.S., Q3 Travelan® sales increased 1% on the prior corresponding period, supported by an improved Amazon.com store, local social media pages, and expanded paid and influencer marketing, partly offset by a stronger Australian dollar against the U.S. dollar. In Canada, after a Q1 pipeline fill into over a thousand retail doors and a 191% Q2 FY26 sales increase over the prior quarter, Q3 FY26 Travelan® sales grew a further 82% on the prior quarter as brand awareness and in-store programs expanded.
Immuron Limited has set up a Small Holding Share Sale Facility for shareholders whose Immuron holdings were worth less than $500 as of the 8 April 2026 Record Date. Based on a closing share price of $0.027, this covers holdings of 18,518 shares or fewer.
Nearly 1,500 of the company’s approximately 2,400 shareholders hold such Small Holdings. These investors can have their shares aggregated and sold without paying brokerage or handling costs, with Immuron covering those expenses. Holders who wish to keep their shares must return a Share Retention Form or increase their holding above $500 in value by 1 June 2026, otherwise their shares will be sold and proceeds remitted to them in Australian dollars.
Immuron Limited reports HY26 global sales revenue of A$4.2 million, up 5% on the prior year, driven by strong Travelan and ProIBS demand. Australian sales rose to A$3.3 million, up 13%, while North American revenue was A$0.9 million, down 18%, though U.S. sales within that increased 17%.
Cash was A$10.0 million at 31 December 2025, up A$7.2 million from 30 June 2025, with EBITDX (ex-R&D) of -A$1.1 million. The company is resetting its strategy by seeking partners for its clinical assets IMM-124E for traveler’s diarrhea and IMM-529 for recurrent C. difficile infection, aiming to have licensees fund further development and commercialization while Immuron focuses on over-the-counter products Travelan and ProIBS.
Immuron Limited reports HY26 global sales revenue of A$4.2 million, up 5% on the prior year, driven by strong Travelan and ProIBS demand. Australian sales rose to A$3.3 million, up 13%, while North American revenue was A$0.9 million, down 18%, though U.S. sales within that increased 17%.
Cash was A$10.0 million at 31 December 2025, up A$7.2 million from 30 June 2025, with EBITDX (ex-R&D) of -A$1.1 million. The company is resetting its strategy by seeking partners for its clinical assets IMM-124E for traveler’s diarrhea and IMM-529 for recurrent C. difficile infection, aiming to have licensees fund further development and commercialization while Immuron focuses on over-the-counter products Travelan and ProIBS.
Immuron Limited reported half-year 2026 revenue of A$4.18 million, up about 5% from the prior year, driven mainly by its Travelan hyperimmune products. Australia led with A$3.19 million in Travelan sales and 11% growth, while U.S. Travelan sales rose 17% to A$0.85 million; Canada declined.
The group’s net loss narrowed to A$1.92 million from A$2.49 million, with gross profit of A$2.65 million and a 63% margin. Hyperimmune products generated operating profit of A$0.98 million, helping lift net assets to A$13.08 million and cash to A$9.99 million after equity raises.
Strategically, Immuron gained FDA approval of an Investigational New Drug application for IMM-529 targeting Clostridioides difficile infection and is positioning the candidate for a Phase 2 trial aimed at recurrent cases. The company also launched PROIBS for irritable bowel syndrome in Australia and continues military-linked collaborations on new oral therapeutics for Campylobacter and Shigella.